当前位置： SCI文献检索 > JOURNAL OF CLINICAL APHERESIS期刊下所有文献 > Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.

Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.

Abstract：

:Plerixafor in combination with granulocyte-colony stimulating factor (G-CSF) is approved for autologous stem cell mobilization in poor mobilizing patients with multiple myeloma or malignant lymphoma. The purpose of this study was to evaluate efficacy and safety of plerixafor in an immediate rescue approach, administrated subsequently to G-CSF alone or chemotherapy and G-CSF in patients at risk for mobilization failure. Eighty-five patients mobilized with G-CSF alone or chemotherapy were included. Primary endpoint was the efficacy of the immediate rescue approach of plerixafor to achieve ≥2.0 × 106 CD34+ cells/kg for a single or ≥5 × 106 CD34+ cells/kg for a double transplantation and potential differences between G-CSF and chemotherapy-based mobilization. Secondary objectives included comparison of stem cell graft composition including CD34+ cell and lymphocyte subsets with regard to the mobilization regimen applied. No significant adverse events were recorded. A median 3.9-fold increase in CD34+ cells following plerixafor was observed, resulting in 97% patients achieving at least ≥2 × 106 CD34+ cells/kg. Significantly more differentiated granulocyte and monocyte forming myeloid progenitors were collected after chemomobilization whereas more CD19+ and natural killer cells were collected after G-CSF. Fifty-two patients underwent transplantation showing rapid and durable engraftment, irrespectively of the stem cell mobilization regimen used. The addition of plerixafor in an immediate rescue model is efficient and safe after both, G-CSF and chemomobilization and results in extremely high success rates. Whether the differences in graft composition have a clinical impact on engraftment kinetics, immunologic recovery, and graft durability have to be analysed in larger prospective studies.

journal_name

J Clin Apher

journal_title

Journal of clinical apheresis

authors

Worel N,Fritsch G,Agis H,Böhm A,Engelich G,Leitner GC,Geissler K,Gleixner K,Kalhs P,Buxhofer-Ausch V,Keil F,Kopetzky G,Mayr V,Rabitsch W,Reisner R,Rosskopf K,Ruckser R,Zoghlami C,Zojer N,Greinix HT

doi

10.1002/jca.21496

subject

Has Abstract

pub_date

2017-08-01 00:00:00

pages

224-234

issue

eissn

0733-2459

issn

1098-1101

journal_volume

pub_type

杂志文章

在线工具

Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.